FR-229934

• UNSPSC Description:

  FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/fr-229934.html

• Purity:

  98.65

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C2N=C(C)N(CC3=CC=C(Cl)C(Cl)=C3)C2=C1)NS(=O)(CCCCC)=O

• Molecular Weight:

  468.40

• References & Citations:

  [1]PANDYA J, et, al. Liquid oral formulations for pde v inhibitors. WO2019130052A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  799841-02-4